A wide range of comorbid conditions are associated with psoriasis, many studies have drawn attention to a higher prevalence of psychiatric comorbidities in psoriatic population. Herein, we present a case of a Caucasian 44-years-old man suffering from a severe schizophrenia, who received guselkumab (a human monoclonal antibody targeting the p40 subunit of IL-23) for the treatment of a moderate-to-severe plaque type psoriasis. After 3 months, the patient reached complete resolution of psoriasis without any side effects, maintained at 6 months follow up visit. Some studies have highlighted the hypothesis that an hyperactivation of immune response appears to be one of the main mechanisms underlying the increased risk of this association. In particular, the axis il-17/il-23 plays a central role in the pathogenesis of this disease. Further research will be needed to assess whether anti-IL23 drugs could be a more suitable therapeutic option in psoriatic patients with schizophrenia.

Guselkumab for the treatment of severe plaque psoriasis in a schizophrenia patient. A case report / Bernardini, Nicoletta; Skroza, Nevena; Prevete, Elisabeth; Marraffa, Federica; Proietti, Ilaria; Tolino, Ersilia; Mambrin, Alessandra; Rossi, Giovanni; Volpe, Salvatore; Bersani, Giuseppe; Potenza, Concetta. - In: DERMATOLOGY REPORTS. - ISSN 2036-7406. - 14:4(2022), pp. 1-2. [10.4081/dr.2022.9476]

Guselkumab for the treatment of severe plaque psoriasis in a schizophrenia patient. A case report

Bernardini, Nicoletta
;
Skroza, Nevena;Prevete, Elisabeth;Marraffa, Federica;Tolino, Ersilia;Mambrin, Alessandra;Volpe, Salvatore;Bersani, Giuseppe;Potenza, Concetta
2022

Abstract

A wide range of comorbid conditions are associated with psoriasis, many studies have drawn attention to a higher prevalence of psychiatric comorbidities in psoriatic population. Herein, we present a case of a Caucasian 44-years-old man suffering from a severe schizophrenia, who received guselkumab (a human monoclonal antibody targeting the p40 subunit of IL-23) for the treatment of a moderate-to-severe plaque type psoriasis. After 3 months, the patient reached complete resolution of psoriasis without any side effects, maintained at 6 months follow up visit. Some studies have highlighted the hypothesis that an hyperactivation of immune response appears to be one of the main mechanisms underlying the increased risk of this association. In particular, the axis il-17/il-23 plays a central role in the pathogenesis of this disease. Further research will be needed to assess whether anti-IL23 drugs could be a more suitable therapeutic option in psoriatic patients with schizophrenia.
2022
guselkumab; psoriasis; schizophrenia
01 Pubblicazione su rivista::01i Case report
Guselkumab for the treatment of severe plaque psoriasis in a schizophrenia patient. A case report / Bernardini, Nicoletta; Skroza, Nevena; Prevete, Elisabeth; Marraffa, Federica; Proietti, Ilaria; Tolino, Ersilia; Mambrin, Alessandra; Rossi, Giovanni; Volpe, Salvatore; Bersani, Giuseppe; Potenza, Concetta. - In: DERMATOLOGY REPORTS. - ISSN 2036-7406. - 14:4(2022), pp. 1-2. [10.4081/dr.2022.9476]
File allegati a questo prodotto
File Dimensione Formato  
Bernardini_Guselkumab_2022.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 1.42 MB
Formato Adobe PDF
1.42 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1652945
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact